| Description | AZT-PMPA, an aryl phosphate derivative of AZT and a nucleoside analogue, demonstrates anti-HIV activity[1]. As a nucleoside reverse transcriptase inhibitor (NRTI), AZT-PMPA targets HIV infection effectively[2]. |
| In vitro | Azt-pmap inhibits virus replication[1]. Azt-pmap shows anti-HIV-1 activities in infected C8166 and JM cells with EC50s of 0.08 and0.32 μM, respectively and it also displays toxicities in infected C8166 and JM cells with TC50s of 500 μM, respectively. |
| molecular weight | 508.42 |
| Molecular formula | C20H25N6O8P |
| CAS | 142629-81-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. McGuigan C, et al. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992 Apr;17(4):311-21. 2. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. |